Staidson (Beijing) BioPharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Staidson (Beijing) BioPharmaceuticals has a total shareholder equity of CN¥1.0B and total debt of CN¥26.4M, which brings its debt-to-equity ratio to 2.5%. Its total assets and total liabilities are CN¥1.3B and CN¥252.7M respectively.
Key information
2.5%
Debt to equity ratio
CN¥26.39m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥43.49m |
| Equity | CN¥1.05b |
| Total liabilities | CN¥252.71m |
| Total assets | CN¥1.30b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 300204's short term assets (CN¥204.3M) exceed its short term liabilities (CN¥179.1M).
Long Term Liabilities: 300204's short term assets (CN¥204.3M) exceed its long term liabilities (CN¥73.6M).
Debt to Equity History and Analysis
Debt Level: 300204 has more cash than its total debt.
Reducing Debt: 300204's debt to equity ratio has increased from 0% to 2.5% over the past 5 years.
Debt Coverage: 300204's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 300204's interest payments on its debt are well covered by EBIT.